Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 12/20 | 0.34 |
| ▸ | NPY2R | P49146 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003680 | 1.00 | GAA (0.35) | GAANPY5RNPY2R | |
| SCHEMBL2669016 | 0.84 | — | — | |
| SCHEMBL1857590 | 0.83 | GAA (0.42) | GAANPY5R | |
| SCHEMBL1857588 | 0.83 | GAA (0.42) | GAANPY5R | |
| SCHEMBL1857589 | 0.83 | GAA (0.42) | GAANPY5R | |
| SCHEMBL1107460 | 0.83 | GAA (0.40) | GAANPY5RNPY2R | |
| SCHEMBL2642020 | 0.83 | NPY5R (0.34) | GAANPY5RNPY2R | |
| SCHEMBL2642173 | 0.83 | NPY5R (0.34) | GAANPY5RNPY2R | |
| SCHEMBL2643987 | 0.74 | GAA (0.44) | GAANPY5RNPY2R | |
| SCHEMBL1107378 | 0.74 | GAA (0.44) | GAANPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745491-B2 | Substituted phenylacetamides and their use as glucokinase activators | PROSIDION LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | PROSIDION LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| US-20080293741-A1 | Tricyclo Substituted Amides as Glucokinase Modulators | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| EP-1740560-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | Prosidion Limited (GB) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103021-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | PROSIDION LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | IAPP, GPR119, CPT1A | GAA 107/4885NPY5R 505/4885NPY2R 533/4885 |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | GCK, KHK, GCKR | GAA 254/4885NPY5R 3624/4885NPY2R 3497/4885 |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | GPR119, SLC5A2, SLC5A1 | GAA 1397/4885NPY5R 907/4885NPY2R 463/4885 |
| US-20080293741-A1 | Tricyclo Substituted Amides as Glucokinase Modulators | GCK, GCKR, GALK1 | GAA 159/4885NPY5R 3869/4885NPY2R 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.